To include your compound in the COVID-19 Resource Center, submit it here.

Tools & Techniques

Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs

With a $30 million series A round led by Andreessen Horowitz, Octant is using genetic bar codes to sort out the pathways behind the therapeutic effects of dirty GPCR modulators, and developing new agents with...

Biopharma must step up for those on the front lines of COVID-19

While not every biotech can develop countermeasures for COVID-19, nearly all can contribute by providing urgently needed resources to protect the clinicians and other essential workers holding the line against catastrophe, and by making their...

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

Deploying its HPV serology testing lab to validate COVID-19 assays is one of three ways NIH’s National Cancer Institute is retooling cancer research activities to take on the pandemic. In a virtual advisory committee meeting...

U.K. consortium to map COVID-19 spread with genome sequencing

To inform public health measures to control the novel coronavirus outbreak, the U.K. has launched the COVID-19 Genomics UK Consortium to track viral spread and evolution via genome sequencing of COVID-19 samples. The group, with...

COVID-19 crisis brings CRISPR-Cas13 research into the spotlight

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA. With diagnostics one of the most critical components...

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...

NCATS, FDA meeting shines light on AAV manufacturing innovation

Technologies highlighted at a NCATS-FDA AAV manufacturing workshop could ramp up the production and durability of gene therapies, but questions remain about who will test drive these innovations and where the next wave of them...

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...

Insilico offers AI-based chemistry to coronavirus response

Insilico Medicine Inc. became the second AI company this week to contribute the speed of its platform to biopharma’s mass mobilization against the 2019-nCoV crisis. As the debate continues about whether AI can transform medicinal...

Cellular fluorescence assay to assess allosteric modulator potency in drug discovery

Karolinska, Pasteur and UCSD researchers have developed a cellular fluorescence assay that can efficiently screen for potent transcription factor allosteric modulators during lead identification. Unlike compounds that work by binding targets’ active sites, allosteric modulators...

Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...

Mammoth eyes CRISPR-based therapeutics with new funding

With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range...

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s links to human...

JV to combine technologies into one gene and cell therapy manufacturing platform

Two manufacturing deals Tuesday underscore manufacturing's vital role in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, will combine the partners' scalable technologies...